Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide effects on brain reward and satiety circuits in obesity and type 2 diabetes
NL-OMON36430Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2011
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of exenatide, exendin 9-39, somatostatin, human insulin, glucagon and 1 more in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Vrije University Medical Center. Started Jul 2011; status: active, not recruiting.
02
Drugs
exenatideexendin 9-39somatostatinhuman insulinglucagon
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON36430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36430.